exRNAdisease

General Information

Database ID:

exR0078484

RNA Name:

PARP1

RNA Type:

mRNA

Chromosome:

chr1

Starnd:

Coordinate:

Start Site(bp):

226360691

End Site(bp):

226408093

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ABHD14B	chr3	51968510	51983409	-
ABL1	chr9	130713016	130887675	+
ABRACL	chr6	139028745	139043302	+
ABTB1	chr3	127672935	127680926	+
AC010323.1	chr19	8308283	8321379	-
AC010422.3	chr19	12643831	12648397	-
AC011462.1	chr19	41350853	41425001	+
AC027796.3	chr17	3585149	3636249	-
AC048338.1	chr12	122207779	122266423	-
AC245033.1	chr15	82536788	82573194	-
ACOT13	chr6	24667035	24705065	+
ACSF2	chr17	50426158	50474845	+
ACTB	chr7	5527148	5563784	-
ACTG1	chr17	81509971	81523847	-
ADGRA3	chr4	22345071	22516066	-
ADH5	chr4	99070978	99088801	-
ADRM1	chr20	62302093	62308862	+
AGL	chr1	99850361	99924023	+
AL117348.2	chr1	225886696	225924278	-
AL162417.1	chr9	133098121	133163914	-
ALDOA	chr16	30064164	30070457	+

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-155-5p	chr21	25573983	25574006	+
hsa-miR-496	chr14	101060628	101060649	+
hsa-miR-556-3p	chr1	162342600	162342621	+
hsa-miR-4700-3p	chr12	120723233	120723258	+

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC009831.1	chr18	31942575	31944156	+
AC106864.1	chr4	112693047	112706810	-
AC132217.1	chr11	2129121	2129964	-
AC245014.3	chr1	145281116	145281462	+
AC245033.4	chr15	82533175	82540008	-
AD000090.1	chr19	35557956	35581954	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference